Tharimmune, Inc. (THAR)
NASDAQ: THAR · Real-Time Price · USD
1.280
-0.040 (-3.03%)
Aug 15, 2025, 10:16 AM - Market open

Tharimmune Stock Forecast

THAR's stock price has decreased by -57.59% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Tharimmune stock has a target of 17, which predicts a 1,228.13% increase from the current stock price of 1.28.

Price Target: $17 (+1,228.13%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$17$17$17$17
Change+1228.1%+1228.1%+1228.1%+1228.1%
* Price targets were last updated on Dec 6, 2024.

Analyst Ratings

According to 1 stock analyst, the rating for Tharimmune is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingJul '25Aug '25
Strong Buy11
Buy00
Hold00
Sell00
Strong Sell00
Total11

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Rodman & Renshaw
Rodman & Renshaw
Strong Buy
Initiates
$17
Strong BuyInitiates$17+1,228.13%Dec 6, 2024
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-7.20
from -9.41
EPS Next Year
-0.07
from -7.20
Fiscal YearFY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
-------
Revenue Growth
-------
EPS
-142.82-130.16-280.76-107.02-9.41-7.20-0.07
EPS Growth
-------
Forward PE
-------
No. Analysts
-----33
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue20252026
Highn/an/a
Avgn/an/a
Lown/an/a

Revenue Growth

Revenue Growth20252026
High--
Avg--
Low--

EPS Forecast

EPS20252026
High-7.41-0.07
Avg-7.20-0.07
Low-6.92-0.07

EPS Growth

EPS Growth20252026
High--
Avg--
Low--
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.